Background. The effect of achieved blood pressure (BP) on first stroke and renal function decline among hypertensive patients with mild to moderate chronic kidney disease (CKD) is still uncertain. Methods. In total, 3230 hypertensive patients with estimated glomerular filtration rate 30-60 mL/min/1.73 m 2 and/or proteinuria were included in the present analyses. Eligible participants were randomly assigned to a daily treatment of a combined enalapril 10 mg and folic acid 0.8 mg tablet or an enalapril 10 mg tablet alone. Participants were followed up every 3 months. The study outcomes included first stroke and the progression of CKD. Results. The median antihypertensive treatment duration was 4.7 years. Compared with participants with a time-averaged ontreatment systolic blood pressure (SBP) of 135 to 140 mmHg, the incidence of total first stroke [1.7% versus 3.3%; hazard ratio (HR), 0.51; 95% confidence interval (CI): 0.26-0.99] and ischemic stroke (1.3% versus 2.8%; HR, 0.46; 95% CI: 0.22-0.98) decreased significantly in those with a time-averaged SBP of 135 mmHg. Furthermore, a time-averaged diastolic blood pressure (DBP) of 80 mmHg, compared with a time-averaged DBP level of 80 to 90 mmHg, was significantly related to a decreased risk of hemorrhagic stroke (0.2% versus 0.9%; HR, 0.18; 95% CI: 0.04-0.80). However, compared with participants with a time-averaged SBP of 135 to 140 mmHg, a lower but non-significant trend of CKD progression was found in those with a time-averaged SBP of 130 mmHg. Conclusions. A BP treatment level of 135/80 mmHg, compared with a BP treatment level of 135-140/80-90 mmHg,
0.45; 95% CI: 0.27-0.76] among patients with mild-to-moderate CKD [14] . Furthermore, a previous post hoc analysis of the CSPPT reported that a low systolic blood pressure (SBP) level of 120-130 mmHg, when compared with the higher target SBP range of 130-140 mmHg and the lower SBP range of <120 mmHg, resulted in the lowest risk of first stroke in general hypertensive patients with normal renal function and without CVD or diabetes [15] . The current study, a post hoc analysis of the CSPPT and the renal sub-study of the CSPPT, aimed to test the impact of achieved BP on first stroke and renal function decline among hypertensive patients with mild-to-moderate CKD.
M A T E R I A L S A N D M E T H O D S

Study participants and design
The rationale and study design for the CSPPT and the renal sub-study of the CSPPT have been described previously [13] . Briefly, the CSPPT was a multi-community, randomized, double-blind, controlled trial conducted from 19 May 2008 to 24 August 2013 in 32 communities in Jiangsu (20 communities) and Anhui (12 communities) provinces. The study enrolled a total of 20 702 hypertensive adults without a history of CVD. The renal sub-study enrolled CSPPT participants from the 20 communities in Jiangsu province, excluding those with an estimated glomerular filtration rate (eGFR) of <30 mL/min/ 1.73 m 2 or who were missing eGFR at baseline. The CSPPT was approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China (FWA assurance number: FWA00001263) and registered with ClinicalTrials.gov, NCT00794885.
Detailed inclusion and exclusion criteria for the CSPPT are described elsewhere [13] . Participants with an eGFR <60 mL/ min/1.73 m 2 and/or proteinuria at baseline were classified as having CKD [14] .
The present study was a post hoc analysis of the CSPPT (stroke outcomes) and the renal sub-study of the CSPPT (renal outcomes). Participants with eGFR 30-60 mL/min/1.73 m 2 and/or proteinuria at baseline were included.
Intervention and follow-up
Eligible participants were randomly assigned, in a 1:1 ratio, to one of two treatment groups: a daily oral dose of one tablet containing 10 mg enalapril and 0.8 mg folic acid (single tablet combination, the enalapril-folic acid group), or a daily oral dose of one tablet containing 10 mg enalapril only (the enalapril alone group). If BP was not properly controlled during the study period, other classes of antihypertensive medications could be prescribed concomitantly, with the exception of angiotensinconverting enzyme inhibitors (ACEIs) or angiotensin type I receptor blockers (ARBs). However, BP control within a normal range [SBP <140 mmHg and diastolic blood pressure (DBP) <90 mmHg] was not mandatory.
Participants were followed up every 3 months. At each visit, BP measurements for each participant were taken, the number of pills taken between visits was counted, and concomitant medications and adverse events were recorded. Seated BP measurements were obtained by trained research staff after the patients had rested for 10 min using a mercury manometer, according to standard methods and using appropriately sized cuffs. Triplicate measurements on the same arm were taken, with at least 2 min between readings. The mean SBP and DBP of the three independent measures were used in analysis.
Laboratory assays
Methylenetetrahydrofolate reductase (MTHFR) C677T (rs1801133) polymorphisms were detected on an ABI Prism 7900HT sequence detection system (Life Technologies, Carlsbad, CA, USA) using the TaqMan assay. Serum creatinine, lipids, fasting glucose and total homocysteine were measured using automatic clinical analyzers (Beckman Coulter, Brea, CA, USA) at the core laboratory of the National Clinical Research Center for Kidney Disease, Guangzhou, China. Specifically, serum creatinine was measured using an enzymatic assay that had been calibrated to be isotope dilution mass spectrometry traceable. Proteinuria was determined using a dipstick test (Dirui-H100, Changchun, Jilin, China). eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation [16] .
Outcomes
The primary outcome was a first nonfatal or fatal stroke (ischemic or hemorrhagic), excluding subarachnoid hemorrhage and silent stroke. Secondary outcomes included a composite of cardiovascular events consisting of cardiovascular death, myocardial infarction (MI) and stroke and all-cause death.
Renal outcomes include the following: (i) progression of CKD, defined as a decrease in eGFR of 30% or more and to a level of <60 mL/min/1.73 m 2 at the exit visit, or ESRD (eGFR <15 mL/min/1.73 m 2 or need for dialysis) and (ii) rapid decline in eGFR, defined as an average decline in eGFR of 5 mL/ min/1.73 m 2 or more per year.
Statistical analysis
Of the 20 702 randomized participants in the CSPPT, 3230 participants with eGFR 30-60 mL/min/1.73 m 2 and/or proteinuria were included in the current analysis. There were missing values on serum total cholesterol (TC) (n ¼ 42), body mass index (BMI, n ¼ 2), smoking status (n ¼ 2), drinking status (n ¼ 2), serum total homocysteine (n ¼ 31), serum fasting glucose (n ¼ 43) and eGFR levels (n ¼ 44) at baseline. Of the 15 104 randomized participants in the renal sub-study of the CSPPT, 1403 participants with eGFR 30-60 mL/min/1.73 m 2 and/or proteinuria were included in the final renal outcome analyses. Multiple imputation was used to deal with missing values in the outcome multivariate-adjusted analyses.
Time-averaged BP levels during the treatment period were calculated for each participant using all post-baseline results up to the last visit prior to the date of an event or at the end of follow-up in those without an event. Participants were divided into groups according to time-averaged SBP levels of 130, 130 to 135, 135 to 140 (reference), 140 to 145 and >145 mmHg. Moreover, to avoid the potential of arbitrary grouping, we also divided participants according to quintiles of were also used to determine any differences between the reference group 135 to 140 mmHg and the other time-averaged SBP categories with the Bonferroni correction. Cox proportional hazards models were used to estimate the HRs and 95% CI for the risk of study outcomes including stroke, ischemic stroke, hemorrhagic stroke, composite cardiovascular events and all-cause death; logistic regression models were used to estimate the ORs and 95% CI for the risk of renal outcomes associated with the time-averaged BP levels and were presented as both crude models and adjusted models after adjustment for age, sex, study centers, MTHFR C677T polymorphism, study treatment groups, BMI, SBP, eGFR, fasting glucose, TC and urinary protein at baseline.
A two-tailed P < 0.05 was considered to be statistically significant in all analyses. R software, version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria; http://www.R-pro ject.org/) was used for all statistical analyses.
R E S U L T S
Study participants and baseline characteristics
A total of 3230 participants in the CSPPT with eGFR 30-60 mL/min/1.73 m 2 and/or proteinuria at baseline were included in the analyses. The flow of the participants is presented in Supplementary data, Figure S1 . Compared with the entire cohort of the CSPPT (n ¼ 20 702), patients with CKD tended to have higher levels of SBP, DBP, fasting glucose and homocysteine, and were more likely to be older, male, smokers and under antihypertensive treatment at baseline (Table 1) . Of the 3230 participants, 2987 (92.8%) had proteinuria. Baseline characteristics of the five groups of CKD participants according to the time-averaged SBP levels ( 130, 130 to 135, 135 to 140, 140 to 145 and >145 mmHg) during the treatment period are summarized in Table 1 . Comparing highest to lowest, participants were more likely to be older, female and to have higher baseline BP levels and fasting glucose concentrations.
A total of 1403 participants in the renal sub-study of the CSPPT with eGFR 30-60 mL/min/1.73 m 2 and/or proteinuria at baseline was included in the analyses of renal outcomes (Supplementary data, Figure S2 ). Baseline characteristics of these participants are presented in Supplementary data, Table S1 .
Impact of time-averaged BP during the treatment period on renal outcomes
For the primary renal outcome (progression of CKD), the median length of follow-up was 4.3 years (interquartile range, 4.1-4.6). A median of 16 (interquartile range, 14-18) BP measurements was taken during the treatment period.
The associations between time-averaged BP and the progression of CKD or rapid decline in eGFR are presented in Supplementary data, Figure S3 and Table S2  and Table 2 . Overall, no significant associations between time-averaged BP and renal outcomes were observed. However, compared with participants with a time-averaged SBP of 135 to 140 mmHg, those with a time-averaged SBP of <130 mmHg showed a lower trend (2.7% versus 3.7%; OR, 0.89; 95% CI: 0.28-2.80) and those with a time-averaged SBP of >145 mmHg showed a higher trend (5.8% versus 3.7%; OR, 1.45; 95% CI: 0.66-3.20) for the risk of CKD progression ( Table 2 ).
Impact of time-averaged BP during the treatment period on first stroke
For the primary outcome (first stroke), the median length of follow-up was 4.7 years (interquartile range, 4.3-4.9). A median of 16 (interquartile range, 12-18) BP measurements was taken during the treatment period.
Overall, the risks of total first stroke (per 5 mmHg decrement; HR, 0.79; 95% CI: 0.75-0.83) and ischemic stroke (per 5 mmHg decrement; HR, 0.82; 95% CI: 0.77-0.87) decreased with the reduction of time-averaged SBP during the treatment period. Compared with participants with a timeaveraged SBP of 135 to 140 mmHg, the incidence of total first stroke (1.7% versus 3.3%; HR, 0.51; 95% CI: 0.26-0.99) and ischemic stroke (1.3% versus 2.8%; HR, 0.46; 95% CI: 0.22-0.98) decreased significantly in those with a timeaveraged SBP of 135 mmHg. Furthermore, a greater risk reduction was observed in participants with a time-averaged SBP of 130 mmHg (total first stroke: 1.3% versus 3.3%; HR, 0.39; 95% CI: 0.15-0.98; ischemic stroke: 1.1% versus 2.8%; HR, 0.39; 95% CI: 0.14-1.08) (Table 3) . Consistently, the risk of total first stroke and ischemic stroke increased along with the increase in quintiles of time-averaged SBP during the treatment period (P for trend <0.001) (Figure 1 ). Similar trends were observed for hemorrhagic stroke, the composite of cardiovascular events and all-cause death (Table 3 and Supplementary data, Table S3 and Figure S4 ). Moreover, similar results were found in participants with proteinuria (Supplementary data, Table S4 ) or eGFR <60 mL/ min/1.73 m 2 (Supplementary data, Table S5 ) at baseline. The risk of total first stroke (per 5 mmHg decrement; HR, 0.67; 95% CI: 0.61-0.73), ischemic stroke (per 5 mmHg decrement; HR, 0.68; 95% CI: 0.62-0.76) and hemorrhagic stroke (per 5 mmHg decrement; HR, 0.58; 95% CI: 0.48-0.69) also decreased with the reduction of time-averaged DBP during the treatment period. Compared with participants with a time-averaged DBP of 80 to 90 mmHg, the incidence of hemorrhagic stroke decreased significantly in those with a timeaveraged DBP of 80 mmHg (0.2% versus 0.9%; HR, 0.18; 95% CI: 0.04-0.80) ( Table 4 ). Similar trends were observed for the composite of cardiovascular events and all-cause death (Supplementary data, Table S6 ).
Stratified analyses for first stroke
Stratified analyses were performed by sex, age (<60 versus !60 years), baseline SBP levels (<160 versus !160 mmHg), eGFR levels (30-90 versus !90 mL/min/1.73 m 2 ) and study treatment groups (enalapril versus enalapril þ folic acid). A lower risk of first stroke was observed in patients with a timeaveraged SBP 135 mmHg (versus 135 to 140 mmHg) in all subgroups (Figure 2 ).
D I S C U S S I O N
This study demonstrates for the first time that a SBP treatment level of 135 mmHg, compared with a SBP treatment level of 135 to 140 mmHg, was significantly associated with a decreased risk of first stroke, especially ischemic stroke. Furthermore, a DBP treatment level of 80 mmHg, compared with a DBP treatment level of 80 to 90 mmHg, was related to 
a lower rate of hemorrhagic stroke in hypertensive patients with mild-to-moderate CKD. In fact, most previous BP-lowering trials conducted in CKD participants, including the Modification of Diet in Renal Disease (MDRD) Study [17] , the African American Study of Kidney Disease and Hypertension (AASK) Study [18] and the Blood-Pressure Control for Renoprotection in Patients with Non-diabetic Chronic Renal Disease (REIN-2) study [19] , failed to show any benefit in clinical outcomes for the low versus usual BP targets. However, the 2012 Kidney Disease: Improving Global Outcomes guidelines suggest a BP treatment target of <140/90 mmHg in CKD patients who have no proteinuria and a stricter target of <130/80 mmHg in CKD patients with proteinuria [11] . The recommendation was primarily based on the post hoc or subgroup analyses of the AASK study [low BP target, mean arterial pressure (MAP) 92 mmHg; usual BP target, MAP 102-107 mmHg] [18, 20] and the MDRD study (low BP target, MAP 92 mmHg; usual BP target, MAP 107 mmHg) [21] , both of which showed a benefit with regard to kidney outcomes with a lower target BP in specific groups, such as patients with higher urine protein levels. More importantly, it should be noted that in both the MDRD study and the AASK study, MAP was targeted rather than SBP and DBP, and a specific MAP may translate into different SBP and DBP treatment goals, depending on the individual participant. Therefore, the 2013 European Society of Hypertension-European Society of Cardiology guidelines [22] and the 2014 JNC-8 report [23] recommend a SBP goal of <140/90 mmHg in patients with CKD. This difference in guidelines illustrates that the evidence to determine the ideal BP goal in CKD patients is scanty and confusing.
Most importantly, there have been few BP target trials involving CKD patients focused on hard CVD outcomes. The Hypertension Optimal Treatment (HOT) study included patients with DBP levels between 100 mmHg and 115 mmHg The association between time-averaged SBP by quintiles and risk of first stroke (A), and first ischemic stroke (B). Adjusted for age, sex, study centers, study treatment groups, MTHFR C677T polymorphisms, BMI, SBP, eGFR, fasting glucose, TC and urinary protein at baseline. , n ¼ 2646) at baseline, there were no differences between the two groups in the primary composite outcome (MI, other acute coronary syndromes, stroke, heart failure or death from cardiovascular causes) [25] . However, a post hoc analysis of the Irbesartan Diabetic Nephropathy Trial, which included adults who had overt diabetic nephropathy and a baseline 24-h urine protein of >0.9 g/day, reported that progressively lower achieved SBP to 120 mmHg predicted a decrease in cardiovascular mortality and congestive heart failure (CHF). A SBP below this threshold was associated with increased risks for cardiovascular deaths and CHF events [26] . In the sub-study of the Action to Control Cardiovascular Risk in Diabetes study, among participants with type 2 diabetes and mild-to-moderate CKD (>76.8% with albuminuria) at baseline, an intensive BP treatment (SBP <120 mmHg, mean: 122 mmHg) was associated with a trend toward reduced rates for stroke (HR, 0.62; 95% CI: 0.36-1.08), when compared with a standard BP treatment (SBP <140 mmHg, mean: 134 mmHg) [27] . Consistently, our current study included participants with mild-to-moderate CKD, of which 92.8% had proteinuria at baseline. Compared with participants with a time-averaged SBP of 135 to 140 mmHg, the incidence of stroke decreased significantly in patients with a time-averaged SBP of 135 mmHg. Furthermore, a time-averaged DBP of 80 mmHg, compared with a DBP level of 80 to 90 mmHg, was significantly related to a decreased risk of hemorrhagic stroke. These results suggest that the presence of proteinuria may possibly modify the effect of intensive BP reduction on CVD outcomes in patients with CKD. These results still warrant further confirmation.
We did not observe a significant association between treated BP and renal function decline. There are several possible explanations for this outcome. First, the current study did not have enough power to test the relationship of treated BP with CKD progression. Second, most of the patients had an eGFR level of !60 mL/min/1.73 m 2 . This study also had several limitations. First, this was a post hoc analysis of the CSPPT. Despite extensive adjustments for known factors, we could not exclude the possibility that unrecorded risk factors may explain some of our findings. Second, renin-angiotensinsystem blockers (ACEIs or ARBs) have been recommended in the presence of proteinuria [28] . While proteinuria was highly prevalent in the current study, it was a post hoc analysis of the CSPPT, and except for a fixed dose of 10 mg/day enalapril, other ACEIs or ARBs could not be prescribed in the CSPPT. Third, a previous analysis of the CSPPT found that the association between time-averaged SBP and the risk of first stroke followed a U-shaped curve, with increased risks above and below the reference range of 120-130 mmHg in general hypertensive patients with normal renal function and without CVD or diabetes [15] . However, due to the small number of participants and events in the groups with time-averaged SBP <120 mmHg or DBP <70 mmHg, the current study could not evaluate the possible U-shaped relationship between achieved BP and the risk of stroke or all-cause death in hypertensive patients with CKD. Furthermore, although a linear association between time-averaged SBP and the risk of stroke was observed in our study, the number of events in the lower BP categories (<130 mmHg) was rather low. Most importantly, the current study included only 393 patients with eGFR <60 mL/min/1.73 m 2 , and therefore had limited power to examine the association between achieved BP and first stroke in these patients. Due to these limitations, an adequately powered, large-scale, randomized trial in patients with CKD is essential to further explore these important issues.
In conclusion, a BP treatment level of 135/80 mmHg, compared with a BP treatment level of 135-140/80-90 mmHg, 
